阿尔法7尼古丁性乙胆受体在局部粉样蛋白病理的小鼠模型中调解网络功能障碍
Fani Koukouli1,2,3,4, Chun-Lei Zhang5, Ivan Lazarevich6,7
1Institut Pasteur, Université de Paris Cité, Integrative Neurobiology of Cholinergic Systems, Department of Neuroscience, CNRS, UMR 3571, Paris, France.
Molecular psychiatry
|September 23, 2025
概括
阿尔茨海默病涉及胆固醇系统功能障碍. 粉样β早期破坏alpha7尼古丁性乙胆受体,损害大脑网络活动,但其他受体可能提供治疗点.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 病理学 病理学 病理学
背景情况:
- 胆固醇系统功能障碍和粉样β (Aβ) 与阿尔茨海默病 (AD) 有关.
- 连接胆固醇缺陷与阿尔茨海默病理学的精确机制尚未完全理解.
- 早期的AD小鼠模型显示Aβ与前额叶皮质 (PFC) 中的尼古丁乙胆受体 (nAChRs) 的相互作用.
研究的目的:
- 研究胆固醇系统,特别是α7 nAChR在早期AD病变发生过程中的作用.
- 确定潜在的治疗点,以减轻AD中Aβ诱导的神经功能障碍.
主要方法:
- 在醒着的小鼠PFC中体内两光子成像和补丁电生理学.
- 在大脑切片上的电生理学实验.
- 计算建模以了解受体动力学.
- 评估加兰他胺对神经元活动的影响.
主要成果:
- 在AD早期阶段,Aβ会扰乱特定内部神经元中的α7nAChR功能,导致网络活动缺陷.
- 在疾病早期,α7 nAChRs被Aβ阻塞.
- 异构体α5和β2 nAChRs部分失活,代表潜在的治疗点.
- 作为一种乙胆酶抑制剂的加兰胺,通过调节含有α5的nAChRs来降低神经元的过活性.
结论:
- 早期的Aβ积累向α7nAChRs,导致AD中的显著网络功能障碍.
- 部分失活的α5和β2 nAChRs为AD治疗干预提供了有希望的目标.
- 加兰他胺显示出缓解早期AD相关神经元过活性的潜力.
更多相关视频
相关概念视频
Cholinergic Receptors: Nicotinic
5.4K
Nicotinic receptors are ligand-gated ion channels that are activated by acetylcholine and nicotine. Upon activation, they cause a rapid increase in the permeability of cells to K+, Na+, and Ca2+, followed by depolarization and excitation. They are in the autonomic ganglia, skeletal neuromuscular junction, CNS, and adrenal medulla.
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
5.4K
Alzheimer's Disease: Treatment
825
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
825
Cholinergic Receptors: Muscarinic
4.8K
The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine.
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
4.8K
Ligand-Gated Ion Channel Receptor: Gating Mechanism
3.8K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
3.8K
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K


